Matthias Scheffler

Nov 10, 2024 | nature.com | Robert A. Wild |Reinhard Buettner |Matthias Scheffler

AbstractOur recently published K1N2-score robustly predicts KEAP1/NFE2L2-mutations and pathway activation status, while its accessibility might be limited. We tested if the RNA expression data of six pathway-related genes and NQO1-IHC might be a reliable alternative using 348 KEAP1/NFE2L2 mutation-enriched NSCLC.

Oct 9, 2024 | nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more

AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.

Jun 24, 2023 | nature.com | Matthias Scheffler |Luca M. Ghiringhelli

AbstractReliable artificial-intelligence models have the potential to accelerate the discovery of materials with optimal properties for various applications, including superconductivity, catalysis, and thermoelectricity. Advancements in this field are often hindered by the scarcity and quality of available data and the significant effort required to acquire new data.